首页 > 最新文献

Therapeutics and Clinical Risk Management最新文献

英文 中文
A Multi-Centric Comparative Study Between Endoscopy-Assisted Laparoscopic Surgery (EALS) vs Laparoscopic Surgery for the Treatment of Gastric Duplication Cysts in Children. 内镜辅助腹腔镜手术(EALS)与腹腔镜手术治疗儿童胃重复囊肿的多中心比较研究。
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-10-11 eCollection Date: 2023-01-01 DOI: 10.2147/TCRM.S426691
Yanmei Luo, Jie Liu, Zhihui Jiang, Xinghai Yang, Song Lin, Xiaowen Mao

Purpose: To compare and analyze the therapeutic effects of endoscopy-assisted laparoscopic surgery (EALS) and laparoscopic surgery (LS) in the treatment of gastric duplication cysts (GDCs).

Patients and methods: We reviewed the clinical data of children with GDCs who underwent surgical treatment at Hubei Maternal and Child Health Hospital, Yijishan Hospital of Wannan Medical College, and Qingdao Women and Children's Medical Center from September 2014 to November 2022.

Results: The study comprised 29 children with GDCs, including 14 in the EALS group and 15 in the LS group. There was no significant difference between the two groups in terms of age, sex, weight, and cyst size characteristics. There was a significant difference between the two groups in terms of average surgical time (P>0.05), which was 1.100 ± 0.833 hours in the EALS group and 1.933 ± 0.159 hours in the LS group. There was a significant difference between the two groups (P<0.05) in average intraoperative blood loss, which was 7.93 ± 3.81 milliliters in the EALS group and 11.80 ± 2.72 milliliters in the LS group. There was a significant difference between the two groups (P<0.05) in average postoperative fasting time, which was 73.79 ± 8.36 hours in the EALS group and 114.1 ± 9.24 hours in the LS group. There was a significant difference between the two groups (P<0.05) in average postoperative hospital stay, which was 10.21 ± 4.25 days in the EALS group and 14.47 ± 4.36 days in the LS group.

Conclusion: EALS technology can not only shorten surgical time, accurately locate GDCs, reduce injuries, and decrease the probability of complications but also achieve treatment goals safely and reliably.

目的:比较分析内镜辅助腹腔镜手术(EALS)和腹腔镜手术(LS)治疗胃重复囊肿(GDCs)的疗效,结果:本研究包括29名GDCs儿童,其中EALS组14名,LS组15名。两组在年龄、性别、体重和囊肿大小特征方面没有显著差异。两组的平均手术时间有显著差异(P>0.05),EALS组为1.100±0.833小时,LS组为1.933±0.159小时。两组比较有显著性差异(P结论:EALS技术不仅可以缩短手术时间,准确定位GDCs,减少损伤,降低并发症发生的概率,而且可以安全可靠地实现治疗目标。
{"title":"A Multi-Centric Comparative Study Between Endoscopy-Assisted Laparoscopic Surgery (EALS) vs Laparoscopic Surgery for the Treatment of Gastric Duplication Cysts in Children.","authors":"Yanmei Luo,&nbsp;Jie Liu,&nbsp;Zhihui Jiang,&nbsp;Xinghai Yang,&nbsp;Song Lin,&nbsp;Xiaowen Mao","doi":"10.2147/TCRM.S426691","DOIUrl":"10.2147/TCRM.S426691","url":null,"abstract":"<p><strong>Purpose: </strong>To compare and analyze the therapeutic effects of endoscopy-assisted laparoscopic surgery (EALS) and laparoscopic surgery (LS) in the treatment of gastric duplication cysts (GDCs).</p><p><strong>Patients and methods: </strong>We reviewed the clinical data of children with GDCs who underwent surgical treatment at Hubei Maternal and Child Health Hospital, Yijishan Hospital of Wannan Medical College, and Qingdao Women and Children's Medical Center from September 2014 to November 2022.</p><p><strong>Results: </strong>The study comprised 29 children with GDCs, including 14 in the EALS group and 15 in the LS group. There was no significant difference between the two groups in terms of age, sex, weight, and cyst size characteristics. There was a significant difference between the two groups in terms of average surgical time (P>0.05), which was 1.100 ± 0.833 hours in the EALS group and 1.933 ± 0.159 hours in the LS group. There was a significant difference between the two groups (P<0.05) in average intraoperative blood loss, which was 7.93 ± 3.81 milliliters in the EALS group and 11.80 ± 2.72 milliliters in the LS group. There was a significant difference between the two groups (P<0.05) in average postoperative fasting time, which was 73.79 ± 8.36 hours in the EALS group and 114.1 ± 9.24 hours in the LS group. There was a significant difference between the two groups (P<0.05) in average postoperative hospital stay, which was 10.21 ± 4.25 days in the EALS group and 14.47 ± 4.36 days in the LS group.</p><p><strong>Conclusion: </strong>EALS technology can not only shorten surgical time, accurately locate GDCs, reduce injuries, and decrease the probability of complications but also achieve treatment goals safely and reliably.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/77/de/tcrm-19-801.PMC10577250.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41238625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of Balanced Crystalloids versus Normal Saline in Critically Ill Patients: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials. 危重患者平衡类晶体与正常生理盐水的比较:随机对照试验的Meta分析和试验序列分析的系统综述。
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-10-11 eCollection Date: 2023-01-01 DOI: 10.2147/TCRM.S416785
Yi Chen, Yongli Gao

Background: Fluid resuscitation is routinely needed for critically ill patients. However, the optimal choice between crystalloids and normal saline is in heat debate.

Objective: To conduct a meta-analysis comparing normal saline and balanced crystalloids in the treatment of critically ill patients with composite mortality as the primary outcome.

Methods: PubMed, Embase, Medline, Web of Science, and Cochrane Library were searched from inception up to March 2022. Studies of critically ill adult patients assigned to receive normal saline or balanced crystalloids were included. We conducted a meta-analysis using an inverse variance, random-effects model in addition to trial sequential analysis (TSA). The primary outcome was composite mortality. Subgroup analyses were also conducted.

Results: Eighteen full-text studies (n=36,224) were included. Balanced crystalloids were associated with lower mortality compared with normal saline (risk ratio [RR]=0.96; 95% confidential interval [CI] 0.93, 1; p=0.03; I2=0) and lower incidence of acute kidney injury/acute renal failure (RR =0.93; 95% CI = 0.87, 0.99; p=0.03). No significant difference was observed in other outcomes. In the sepsis patients, the balanced crystalloid showed a lower composite mortality rate compared with normal saline (RR =0.91; 95% CI = 0.85, 0.99; p=0.02). TSA analysis demonstrated that, with 80% power, the effect of balanced crystalloid is not larger than a 10% relative decrease in composite mortality compared with normal saline.

Conclusion and relevance: This study demonstrated that balanced crystalloids could be an optimal choice over normal saline in critically ill patients to a reduced composite mortality rate. In patients with sepsis, the difference is especially significant. Nonetheless, the optimal resuscitation fluid option between saline and balanced crystalloid solutions should be investigated further with more evidence.

背景:危重病人通常需要液体复苏。然而,晶体和生理盐水之间的最佳选择仍在激烈争论中。目的:进行一项荟萃分析,比较生理盐水和平衡晶体治疗以复合死亡率为主要结果的危重患者。方法:检索PubMed、Embase、Medline、Web of Science和Cochrane图书馆,从成立到2022年3月。包括对被分配接受生理盐水或平衡晶体治疗的危重成年患者的研究。除了试验序列分析(TSA)外,我们还使用逆方差随机效应模型进行了荟萃分析。主要结果是复合死亡率。还进行了分组分析。结果:纳入18项全文研究(n=36224)。与生理盐水相比,平衡晶体具有较低的死亡率(风险比[RR]=0.96;95%置信区间[CI]0.93,1;p=0.03;I2=0)和较低的急性肾损伤/急性肾衰竭发生率(RR=0.93;95%CI=0.87,0.99;p=0.03)。其他结果无显著差异。在败血症患者中,与生理盐水相比,平衡晶体显示出较低的复合死亡率(RR=0.91;95%CI=0.85,0.99;p=0.02)。TSA分析表明,在80%的功率下,平衡晶体的效果不大于与生理盐水相比较复合死亡率相对降低10%。结论和相关性:本研究表明,在危重患者中,平衡晶体可能是降低复合死亡率的最佳选择,而不是生理盐水。在败血症患者中,这种差异尤其显著。尽管如此,生理盐水和平衡晶体溶液之间的最佳复苏液选择应进一步研究,并提供更多证据。
{"title":"Comparison of Balanced Crystalloids versus Normal Saline in Critically Ill Patients: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials.","authors":"Yi Chen,&nbsp;Yongli Gao","doi":"10.2147/TCRM.S416785","DOIUrl":"10.2147/TCRM.S416785","url":null,"abstract":"<p><strong>Background: </strong>Fluid resuscitation is routinely needed for critically ill patients. However, the optimal choice between crystalloids and normal saline is in heat debate.</p><p><strong>Objective: </strong>To conduct a meta-analysis comparing normal saline and balanced crystalloids in the treatment of critically ill patients with composite mortality as the primary outcome.</p><p><strong>Methods: </strong>PubMed, Embase, Medline, Web of Science, and Cochrane Library were searched from inception up to March 2022. Studies of critically ill adult patients assigned to receive normal saline or balanced crystalloids were included. We conducted a meta-analysis using an inverse variance, random-effects model in addition to trial sequential analysis (TSA). The primary outcome was composite mortality. Subgroup analyses were also conducted.</p><p><strong>Results: </strong>Eighteen full-text studies (n=36,224) were included. Balanced crystalloids were associated with lower mortality compared with normal saline (risk ratio [RR]=0.96; 95% confidential interval [CI] 0.93, 1; p=0.03; <i>I<sup>2</sup></i>=0) and lower incidence of acute kidney injury/acute renal failure (RR =0.93; 95% CI = 0.87, 0.99; p=0.03). No significant difference was observed in other outcomes. In the sepsis patients, the balanced crystalloid showed a lower composite mortality rate compared with normal saline (RR =0.91; 95% CI = 0.85, 0.99; p=0.02). TSA analysis demonstrated that, with 80% power, the effect of balanced crystalloid is not larger than a 10% relative decrease in composite mortality compared with normal saline.</p><p><strong>Conclusion and relevance: </strong>This study demonstrated that balanced crystalloids could be an optimal choice over normal saline in critically ill patients to a reduced composite mortality rate. In patients with sepsis, the difference is especially significant. Nonetheless, the optimal resuscitation fluid option between saline and balanced crystalloid solutions should be investigated further with more evidence.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f6/a1/tcrm-19-783.PMC10577264.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41238644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Application of the Willis Covered Stent in the Treatment of Complex Vascular Diseases of the Internal Carotid Artery and Vertebral Artery: A Retrospective Single-Center Experience. Willis覆膜支架在治疗颈内动脉和椎动脉复杂血管疾病中的应用:单中心回顾性经验。
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-09-25 eCollection Date: 2023-01-01 DOI: 10.2147/TCRM.S417803
Yin-Gang Wu, Bowen Wang, Hao Cui, Hao Zhu, Ge Gao

Objective: To retrospectively evaluate the efficacy and security of Willis covered stent (WCS) deployment for complex vascular diseases of the internal carotid (ICA) and vertebral (VA) arteries.

Methods: Retrospective analysis was performed on complex vascular disease patients (n=36) treated with WCSs at our center between March 2017 and December 2022, with a 3-36-months follow-up surveillance and digital subtraction angiography (DSA) examination.

Results: The WCSs were successfully deployed in all the patients. The 36 included lesions were carotid-cavernous sinus fistulas (CCFs; n=10) (27.8%), complex saccular aneurysms (n=10) (27.8%), traumatic pseudoaneurysms (n=7) (19.4%), blood blister-like aneurysms (BBAs; n=5) (13.9%), and iatrogenic carotid or vertebral artery ruptures (n=4) (11.1%). The WCS was released at the communicating segment (n=2) (5.6%), the ophthalmic segment (n=3) (8.3%), the clinoid and cavernous segment (n=28) (77.8%), the petrous segment (n=2) (5.6%) of ICA and the V3 segment (n=1) (2.8%) of VA. Postoperative DSA showed complete lesion occlusion in 26 patients (72.2%) who were immediately treated with WCSs, and endoleaks occurred in 3 patients (8.3%) (endoleaks resolved postadjustment in 7 patients (19.4%)). In patients (n=3) (8.3%) treated with double stents at the break of the ICA, the endoleak remained in 1 CCF patient (2.8%) during the 3-month follow-up, and the residual shunt disappeared after the second stent system was placed 3 months later. No aneurysm, bleeding or infarct recurrence reported, and only 1 patient (2.8%) had mild asymptomatic in-stent stenosis. Deaths and procedural complications did not occur during follow-up.

Conclusion: Treatment with a WCS for intracranial complex vascular diseases resulted in satisfactory clinical outcomes and appeared effective and safe. Controlled, multicenter, large sample sizes and longer follow-up periods studies are necessary.

目的:回顾性评价Willis覆膜支架(WCS)置入治疗颈内动脉(ICA)和椎动脉(VA)复杂血管疾病的疗效和安全性。方法:对2017年3月至2022年12月在我中心接受WCS治疗的复杂血管疾病患者(n=36)进行回顾性分析,并进行3-36个月的随访监测和数字减影血管造影术(DSA)检查。结果:所有患者均成功部署了WCS。36个病变包括颈动脉海绵窦瘘(CCFs;n=10)(27.8%)、复杂囊状动脉瘤(n=10)、创伤性假性动脉瘤(n=7)(19.4%)、血泡样动脉瘤(BBAs;n=5)(13.9%)和医源性颈动脉或椎动脉破裂(n=4)(11.1%),ICA的斜坡段和海绵状段(n=28)(77.8%)、岩段(n=2)(5.6%)和V3段(n=1)(2.8%),3名患者(8.3%)发生内漏(7名患者(19.4%)调整后内漏消失)。在ICA断裂时接受双支架治疗的患者(n=3)(8.3%,1名CCF患者(2.8%)在3个月的随访中仍存在内漏,3个月后放置第二个支架系统后残余分流消失。没有动脉瘤、出血或梗死复发的报告,只有1名患者(2.8%)出现轻度无症状支架内狭窄。在随访期间没有发生死亡和手术并发症。结论:WCS治疗颅内复杂血管疾病取得了令人满意的临床结果,看起来是有效和安全的。有必要进行对照、多中心、大样本量和更长随访期的研究。
{"title":"Application of the Willis Covered Stent in the Treatment of Complex Vascular Diseases of the Internal Carotid Artery and Vertebral Artery: A Retrospective Single-Center Experience.","authors":"Yin-Gang Wu,&nbsp;Bowen Wang,&nbsp;Hao Cui,&nbsp;Hao Zhu,&nbsp;Ge Gao","doi":"10.2147/TCRM.S417803","DOIUrl":"https://doi.org/10.2147/TCRM.S417803","url":null,"abstract":"<p><strong>Objective: </strong>To retrospectively evaluate the efficacy and security of Willis covered stent (WCS) deployment for complex vascular diseases of the internal carotid (ICA) and vertebral (VA) arteries.</p><p><strong>Methods: </strong>Retrospective analysis was performed on complex vascular disease patients (n=36) treated with WCSs at our center between March 2017 and December 2022, with a 3-36-months follow-up surveillance and digital subtraction angiography (DSA) examination.</p><p><strong>Results: </strong>The WCSs were successfully deployed in all the patients. The 36 included lesions were carotid-cavernous sinus fistulas (CCFs; n=10) (27.8%), complex saccular aneurysms (n=10) (27.8%), traumatic pseudoaneurysms (n=7) (19.4%), blood blister-like aneurysms (BBAs; n=5) (13.9%), and iatrogenic carotid or vertebral artery ruptures (n=4) (11.1%). The WCS was released at the communicating segment (n=2) (5.6%), the ophthalmic segment (n=3) (8.3%), the clinoid and cavernous segment (n=28) (77.8%), the petrous segment (n=2) (5.6%) of ICA and the V3 segment (n=1) (2.8%) of VA. Postoperative DSA showed complete lesion occlusion in 26 patients (72.2%) who were immediately treated with WCSs, and endoleaks occurred in 3 patients (8.3%) (endoleaks resolved postadjustment in 7 patients (19.4%)). In patients (n=3) (8.3%) treated with double stents at the break of the ICA, the endoleak remained in 1 CCF patient (2.8%) during the 3-month follow-up, and the residual shunt disappeared after the second stent system was placed 3 months later. No aneurysm, bleeding or infarct recurrence reported, and only 1 patient (2.8%) had mild asymptomatic in-stent stenosis. Deaths and procedural complications did not occur during follow-up.</p><p><strong>Conclusion: </strong>Treatment with a WCS for intracranial complex vascular diseases resulted in satisfactory clinical outcomes and appeared effective and safe. Controlled, multicenter, large sample sizes and longer follow-up periods studies are necessary.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ca/2c/tcrm-19-773.PMC10541676.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41154002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How to Choose the Appropriate Posterior Slope Angle Can Lead to Good Knee Joint Function Recovery in Total Knee Arthroplasty? 全膝关节置换术中如何选择合适的后倾角能使膝关节功能恢复良好?
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-09-25 eCollection Date: 2023-01-01 DOI: 10.2147/TCRM.S427542
Xi-Qing Pan, Jin-Hui Liu, Jiang-Li Zhang, An Chai, Feng Li, Lei Shu, Wei Zhao

Objective: In this study, we aim to examine the effects of osteotomy under varying posterior slope angles on knee joint function recovery following knee arthroplasty.

Methods: We conducted a retrospective analysis from September 2015 to September 2018 on 240 patients who underwent knee arthroplasty three years previously. The study participants were categorized based on changes in the angle of the posterior slope before and after surgery: Group 1, > 5°; Group 2, 3°-5°; Group 3, 0°-3°; Group 4, -3°-0°; Group 5, < -3°. All participants were affected with knee osteoarthritis. The Knee Society Clinical Rating System (KSS) knee function score, Western Ontario and McMaster Universities Arthritis Index (WOMAC) knee function score, Visual Analogue Scale (VAS) pain score, and postoperative complications were measured 3 years after surgery.

Results: The level of pain experienced by the patients decreased significantly than before, with pain scores ranging from 1.0-3.0, and there was a statistical difference between groups (H = 93.400, P < 0.001). The KSS score increased, with group 5 having the lowest median score of 78.0 and group 2 having the highest median score of 97.0, and there was a statistical difference between groups (H = 164.460, P < 0.001). The WOMAC score was reduced, with the median score being 24.0, 11.0, 14.0, 20.0, and 26.0, in the five groups, respectively. Group 5 had the highest score, while Group 2 had the lowest score, and there was a statistically significant difference between groups (H = 164.223, P < 0.001). No symptoms such as periprosthetic femoral fracture, prosthetic loosening, or pad wear were detected in patients postoperatively.

Conclusion: Osteotomy at various posterior slope angles in total knee arthroplasty impacts postoperative knee function rehabilitation. An excessive increase or decrease in angle can have an impact on the postoperative recovery of knee function.

目的:在本研究中,我们旨在观察不同后倾角下截骨对膝关节置换术后膝关节功能恢复的影响。方法:我们对三年前接受膝关节置换术的240名患者进行了2015年9月至2018年9月的回顾性分析。研究参与者根据手术前后后斜坡角度的变化进行分类:第1组,>5°;第2组,3°-5°;第3组,0°-3°;第4组,-3°-0°;第5组,<-3°。所有参与者均患有膝骨关节炎。术后3年测量膝关节学会临床评分系统(KSS)膝关节功能评分、西安大略大学和麦克马斯特大学关节炎指数(WOMAC)膝功能评分、视觉模拟量表(VAS)疼痛评分和术后并发症。结果:患者的疼痛程度比以前显著降低,疼痛评分在1.0-3.0之间,组间有统计学差异(H=93.400,P=164.460,P<0.001)。WOMAC评分降低,五组的中位评分分别为24.0、11.0、14.0、20.0和26.0。第5组得分最高,第2组得分最低,两组之间差异有统计学意义(H=164.223,P<0.001)。术后患者未出现假体周围股骨骨折、假体松动或衬垫磨损等症状。结论:不同后倾角截骨对全膝关节置换术后膝关节功能的恢复有一定影响。角度的过度增加或减少会影响膝关节功能的术后恢复。
{"title":"How to Choose the Appropriate Posterior Slope Angle Can Lead to Good Knee Joint Function Recovery in Total Knee Arthroplasty?","authors":"Xi-Qing Pan,&nbsp;Jin-Hui Liu,&nbsp;Jiang-Li Zhang,&nbsp;An Chai,&nbsp;Feng Li,&nbsp;Lei Shu,&nbsp;Wei Zhao","doi":"10.2147/TCRM.S427542","DOIUrl":"https://doi.org/10.2147/TCRM.S427542","url":null,"abstract":"<p><strong>Objective: </strong>In this study, we aim to examine the effects of osteotomy under varying posterior slope angles on knee joint function recovery following knee arthroplasty.</p><p><strong>Methods: </strong>We conducted a retrospective analysis from September 2015 to September 2018 on 240 patients who underwent knee arthroplasty three years previously. The study participants were categorized based on changes in the angle of the posterior slope before and after surgery: Group 1, > 5°; Group 2, 3°-5°; Group 3, 0°-3°; Group 4, -3°-0°; Group 5, < -3°. All participants were affected with knee osteoarthritis. The Knee Society Clinical Rating System (KSS) knee function score, Western Ontario and McMaster Universities Arthritis Index (WOMAC) knee function score, Visual Analogue Scale (VAS) pain score, and postoperative complications were measured 3 years after surgery.</p><p><strong>Results: </strong>The level of pain experienced by the patients decreased significantly than before, with pain scores ranging from 1.0-3.0, and there was a statistical difference between groups (<i>H</i> = 93.400, P < 0.001). The KSS score increased, with group 5 having the lowest median score of 78.0 and group 2 having the highest median score of 97.0, and there was a statistical difference between groups (<i>H</i> = 164.460, P < 0.001). The WOMAC score was reduced, with the median score being 24.0, 11.0, 14.0, 20.0, and 26.0, in the five groups, respectively. Group 5 had the highest score, while Group 2 had the lowest score, and there was a statistically significant difference between groups (<i>H</i> = 164.223, P < 0.001). No symptoms such as periprosthetic femoral fracture, prosthetic loosening, or pad wear were detected in patients postoperatively.</p><p><strong>Conclusion: </strong>Osteotomy at various posterior slope angles in total knee arthroplasty impacts postoperative knee function rehabilitation. An excessive increase or decrease in angle can have an impact on the postoperative recovery of knee function.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/71/a2/tcrm-19-767.PMC10540787.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41110517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Speckle-Tracking Echocardiography Predicts Adverse Left Ventricular Remodeling After Valve Replacement in Rheumatic Mitral Stenosis. 斑点追踪超声心动图预测风湿性二尖瓣狭窄瓣膜置换术后左心室重构不良。
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-09-20 eCollection Date: 2023-01-01 DOI: 10.2147/TCRM.S419163
Xiaofeng Zhang, Jiaqi Zhang, Yongzhi Cai, Yue Li, Shiyun Qin, Jingtao Li, Decai Zeng, Tongtong Huang, Liu Liu Huang, Yanfen Zhong, Lihui Wei, Ji Wu

Background: Rheumatic mitral stenosis(RMS) may leads to left ventricular remodeling (LVR), which can persist even after valve surgery. Identifying markers for early structure and function in patients with rheumatic heart disease who are at risk for adverse LVR after surgery can help determine the optimal timing of intervention. This study aimed to investigate whether preoperative parameters of global left ventricular long-axis strain (LVGLS) and mechanical discretization (MD) could predict postoperative adverse LVR.

Methods: A total of 109 adult patients with RMS and 50 healthy controls were enrolled in this study. Baseline clinical features, conventional echocardiography results, LVGLS, and MD were compared between the two groups. Pre- and post-surgery echocardiography measurements were collected, and adverse LVR was defined as a>15% increase in left ventricular end-diastolic volume or >10% decrease in left ventricular ejection fraction. Binary regression analysis was used to determine independent predictors of poor left ventricular remodeling.

Results: The variables associated with adverse LVR in this study were LVGLS (P<0.001, odds ratio: 1.996, 95% CI: 1.394-2.856) and MD (P=0.011, odds ratio: 1.031, 95% CI: 1.007-1.055). The poorly reconstructed group had lower absolute values of LVGLS and higher MD than the healthy control group and the non-poorly reconstructed group. A LVGLS cutoff of -15.0% was the best predictor for patients with poorly reconstructed LVR (sensitivity: 75.7%; specificity: 100.0%; AUC: 0.93), and a MD cutoff of 63.8ms was the best predictor (sensitivity: 63.8%; specificity: 98.6%; AUC: 0.88).

Conclusion: Speckle tracking echocardiography has potential value for predicting the progression of adverse LVR and for identifying non-responders among patients with RMS undergoing surgery.

背景:风湿性二尖瓣狭窄(RMS)可能导致左心室重构(LVR),即使在瓣膜手术后也可能持续。在术后有LVR不良风险的风湿性心脏病患者中,识别早期结构和功能的标志物有助于确定干预的最佳时机。本研究旨在探讨术前整体左心室长轴应变(LVGLS)和机械离散化(MD)参数是否可以预测术后不良LVR。方法:共有109名RMS成年患者和50名健康对照参加本研究。比较两组的基线临床特征、常规超声心动图结果、LVGLS和MD。收集术前和术后超声心动图测量结果,不良LVR定义为左心室舒张末期容积增加>15%或左心室射血分数下降>10%。二元回归分析用于确定不良左心室重构的独立预测因素。结果:本研究中与不良LVR相关的变量为LVGLS(P结论:斑点跟踪超声心动图在预测不良LVR的进展和识别接受手术的RMS患者中的无反应者方面具有潜在价值。
{"title":"Speckle-Tracking Echocardiography Predicts Adverse Left Ventricular Remodeling After Valve Replacement in Rheumatic Mitral Stenosis.","authors":"Xiaofeng Zhang,&nbsp;Jiaqi Zhang,&nbsp;Yongzhi Cai,&nbsp;Yue Li,&nbsp;Shiyun Qin,&nbsp;Jingtao Li,&nbsp;Decai Zeng,&nbsp;Tongtong Huang,&nbsp;Liu Liu Huang,&nbsp;Yanfen Zhong,&nbsp;Lihui Wei,&nbsp;Ji Wu","doi":"10.2147/TCRM.S419163","DOIUrl":"https://doi.org/10.2147/TCRM.S419163","url":null,"abstract":"<p><strong>Background: </strong>Rheumatic mitral stenosis(RMS) may leads to left ventricular remodeling (LVR), which can persist even after valve surgery. Identifying markers for early structure and function in patients with rheumatic heart disease who are at risk for adverse LVR after surgery can help determine the optimal timing of intervention. This study aimed to investigate whether preoperative parameters of global left ventricular long-axis strain (LVGLS) and mechanical discretization (MD) could predict postoperative adverse LVR.</p><p><strong>Methods: </strong>A total of 109 adult patients with RMS and 50 healthy controls were enrolled in this study. Baseline clinical features, conventional echocardiography results, LVGLS, and MD were compared between the two groups. Pre- and post-surgery echocardiography measurements were collected, and adverse LVR was defined as a>15% increase in left ventricular end-diastolic volume or >10% decrease in left ventricular ejection fraction. Binary regression analysis was used to determine independent predictors of poor left ventricular remodeling.</p><p><strong>Results: </strong>The variables associated with adverse LVR in this study were LVGLS (P<0.001, odds ratio: 1.996, 95% CI: 1.394-2.856) and MD (P=0.011, odds ratio: 1.031, 95% CI: 1.007-1.055). The poorly reconstructed group had lower absolute values of LVGLS and higher MD than the healthy control group and the non-poorly reconstructed group. A LVGLS cutoff of -15.0% was the best predictor for patients with poorly reconstructed LVR (sensitivity: 75.7%; specificity: 100.0%; AUC: 0.93), and a MD cutoff of 63.8ms was the best predictor (sensitivity: 63.8%; specificity: 98.6%; AUC: 0.88).</p><p><strong>Conclusion: </strong>Speckle tracking echocardiography has potential value for predicting the progression of adverse LVR and for identifying non-responders among patients with RMS undergoing surgery.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3c/b9/tcrm-19-755.PMC10518172.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41166111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating the Effect of COVID-19 on Outpatient Opioid Utilization Among Health First Colorado Members and a National Non-Medicaid Cohort: An Interrupted Time Series Analysis. 评估新冠肺炎对健康第一科罗拉多州成员和全国非医疗队列中门诊阿片类药物使用的影响:中断时间序列分析。
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-09-18 eCollection Date: 2023-01-01 DOI: 10.2147/TCRM.S424961
Heather D Anderson, Vanessa Paul Patterson, Garth Wright, Julia E Rawlings, Gina D Moore, Jim Leonard, Robert L Page Ii

Objective: COVID-19, coinciding with the opioid epidemic in the United States, has had significant impacts on health-care utilization. While mixed, early analyses signaled a potential resurgence in opioid use following the pandemic. The primary study objective was to assess the association of the COVID-19 pandemic with opioid utilization among Health First Colorado (Colorado's Medicaid Program) members and a non-Medicaid managed care cohort who did not have a diagnosis of cancer or sickle cell disease.

Patients and methods: Using an interrupted time series and segmented regression analysis, this population-level study assessed the association of the COVID-19 pandemic on prescribed utilization of long- and short-acting opioid analgesics among Health First Colorado members and a random sample of non-Medicaid managed care members. Pharmacy claims data for both cohorts were assessed between October 1, 2018, and September 30, 2021, with April 2020 identified as the interruption of interest. We evaluated the following monthly opioid use measures separately for short-acting and long-acting opioids: number of members filling an opioid, total fills, and total days supplied.

Results: Short- and long-acting opioid utilization was significantly decreasing among Health First Colorado members in the 18 months prior to the start of COVID-19. After the onset of the pandemic, utilization stabilized and slopes were not significantly different from zero. Among the non-Medicaid managed care cohort, short- and long-acting opioid utilization significantly decreased in the 18 months leading up to the onset of the pandemic. After the onset of the pandemic, utilization of long-acting opioids stabilized, while utilization of short-acting opioids significantly increased.

Conclusion: While we observed an increase in opioid utilization measures post-pandemic in the non-Medicaid managed care cohort, a similar increase was not observed in Health First Colorado members suggesting that thoughtful opioid policies put in place pre-pandemic may have been effective at controlling potential inappropriate opioid utilization.

目的:新冠肺炎与美国阿片类药物流行同时发生,对医疗保健利用产生了重大影响。尽管喜忧参半,但早期分析表明,在新冠疫情之后,阿片类药物的使用可能会死灰复燃。主要研究目的是评估新冠肺炎大流行与科罗拉多州卫生第一(科罗拉多州医疗补助计划)成员和未被诊断为癌症或镰状细胞病的非医疗补助管理护理队列中阿片类药物使用的关联。患者和方法:使用中断时间序列和分段回归分析,这项人群层面的研究评估了新冠肺炎大流行与健康第一科罗拉多州成员和非医疗补助管理的护理成员中长期和短期阿片类镇痛剂处方使用的关联。两个队列的药房索赔数据在2018年10月1日至2021年9月30日期间进行了评估,其中2020年4月被确定为利息中断。我们分别评估了以下针对短效和长效阿片类药物的月度阿片类使用指标:填充阿片类物质的成员数量、总填充量和供应的总天数。结果:在新冠肺炎开始前的18个月内,科罗拉多州健康第一组织成员的短期和长期阿片类药物使用率显著下降。疫情爆发后,利用率趋于稳定,斜率与零没有显著差异。在非医疗补助管理的护理队列中,在疫情爆发前的18个月内,短期和长期阿片类药物的使用率显著下降。疫情爆发后,长效阿片类药物的利用率稳定下来,而短效阿片类物质的利用率显著增加。结论:虽然我们观察到在非医疗补助管理的护理队列中,阿片类药物使用量在疫情后有所增加,但在科罗拉多州健康第一组织的成员中没有观察到类似的增加,这表明疫情前制定的深思熟虑的阿片类药政策可能有效地控制了潜在的不适当阿片类物质使用。
{"title":"Evaluating the Effect of COVID-19 on Outpatient Opioid Utilization Among Health First Colorado Members and a National Non-Medicaid Cohort: An Interrupted Time Series Analysis.","authors":"Heather D Anderson,&nbsp;Vanessa Paul Patterson,&nbsp;Garth Wright,&nbsp;Julia E Rawlings,&nbsp;Gina D Moore,&nbsp;Jim Leonard,&nbsp;Robert L Page Ii","doi":"10.2147/TCRM.S424961","DOIUrl":"https://doi.org/10.2147/TCRM.S424961","url":null,"abstract":"<p><strong>Objective: </strong>COVID-19, coinciding with the opioid epidemic in the United States, has had significant impacts on health-care utilization. While mixed, early analyses signaled a potential resurgence in opioid use following the pandemic. The primary study objective was to assess the association of the COVID-19 pandemic with opioid utilization among Health First Colorado (Colorado's Medicaid Program) members and a non-Medicaid managed care cohort who did not have a diagnosis of cancer or sickle cell disease.</p><p><strong>Patients and methods: </strong>Using an interrupted time series and segmented regression analysis, this population-level study assessed the association of the COVID-19 pandemic on prescribed utilization of long- and short-acting opioid analgesics among Health First Colorado members and a random sample of non-Medicaid managed care members. Pharmacy claims data for both cohorts were assessed between October 1, 2018, and September 30, 2021, with April 2020 identified as the interruption of interest. We evaluated the following monthly opioid use measures separately for short-acting and long-acting opioids: number of members filling an opioid, total fills, and total days supplied.</p><p><strong>Results: </strong>Short- and long-acting opioid utilization was significantly decreasing among Health First Colorado members in the 18 months prior to the start of COVID-19. After the onset of the pandemic, utilization stabilized and slopes were not significantly different from zero. Among the non-Medicaid managed care cohort, short- and long-acting opioid utilization significantly decreased in the 18 months leading up to the onset of the pandemic. After the onset of the pandemic, utilization of long-acting opioids stabilized, while utilization of short-acting opioids significantly increased.</p><p><strong>Conclusion: </strong>While we observed an increase in opioid utilization measures post-pandemic in the non-Medicaid managed care cohort, a similar increase was not observed in Health First Colorado members suggesting that thoughtful opioid policies put in place pre-pandemic may have been effective at controlling potential inappropriate opioid utilization.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9f/b6/tcrm-19-745.PMC10516188.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41166170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatic Safety of Febuxostat and Allopurinol for Gout Patients: A Systematic Review of Randomized Controlled Trial. 非布索坦和别嘌醇治疗痛风患者的肝脏安全性:随机对照试验的系统评价。
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-09-18 eCollection Date: 2023-01-01 DOI: 10.2147/TCRM.S424598
Christiyanti Dewi, Falerina Puspita, Irma Melyani Puspitasari, Neily Zakiyah

Purpose: This study aims to systematically review the hepatic safety of febuxostat and allopurinol in adult gout patients.

Methods: We searched for information using the following databases: PubMed, Cochrane Library, and Scopus. The inclusion criteria were to review all randomized controlled trials (RCT) that compared allopurinol and febuxostat for adult gout patients that had an assessment of liver function outcomes. Non-English studies on case reports, case series, reviews, and abstracts only were excluded. We extracted information from the studies to answer the research question, ie, study design, publication year, population, sample size, patient characterization, duration, Jadad score, and liver function outcomes.

Results: We screened 512 publications from the databases and identified 11 studies that met the inclusion criteria. Ten out of 11 included studies were double-blind RCTs. In the majority of the included studies, no statistically significant differences were observed in terms of hepatic safety data between febuxostat and allopurinol. However, in studies where allopurinol titration was used, it posed a challenge to maintain blinding. Notably, consistent adverse events related to liver function findings were observed across all reviewed RCTs. These abnormal liver function test results sometimes led to study withdrawal based on the investigators' assessment. Nevertheless, the investigators classified most liver function test elevations as mild to moderate in severity.

Conclusion: Our analysis concluded that adult gout patients enrolled in the included RCTs exhibited similar hepatic safety profiles for both febuxostat and allopurinol treatment. Liver function abnormalities were identified in all RCTs included in this systematic review. Consequently, it is important for the product labeling information of both allopurinol and febuxostat to present and describe the current safety data to guide healthcare practitioners when prescribing these medications to patients. Pharmacovigilance and post-marketing pharmacoepidemiology data are essential in establishing the comprehensive safety profile.

目的:本研究旨在系统评价非布索坦和别嘌醇治疗成年痛风患者的肝脏安全性。方法:我们使用以下数据库搜索信息:PubMed、Cochrane Library和Scopus。纳入标准是审查所有随机对照试验(RCT),这些试验比较了别嘌醇和非布索坦对成年痛风患者的肝功能结果的评估。仅排除关于病例报告、病例系列、综述和摘要的非英语研究。我们从研究中提取信息来回答研究问题,即研究设计、发表年份、人群、样本量、患者特征、持续时间、Jadad评分和肝功能结果。结果:我们从数据库中筛选了512篇出版物,确定了11项符合纳入标准的研究。11项纳入研究中有10项为双盲随机对照试验。在大多数纳入的研究中,非布索坦和别嘌醇在肝脏安全性数据方面没有观察到统计学上的显著差异。然而,在使用别嘌呤醇滴定的研究中,维持致盲性是一个挑战。值得注意的是,在所有审查的随机对照试验中都观察到了与肝功能发现相关的持续不良事件。根据研究人员的评估,这些异常肝功能测试结果有时会导致研究退出。然而,研究人员将大多数肝功能测试升高的严重程度分为轻度至中度。结论:我们的分析得出结论,纳入随机对照试验的成年痛风患者在非布索坦和别嘌醇治疗中表现出相似的肝脏安全性。纳入本系统综述的所有随机对照试验均发现肝功能异常。因此,别嘌醇和非布司他的产品标签信息必须呈现和描述当前的安全性数据,以指导医疗从业者在给患者开这些药物时。药物警戒和上市后药物流行病学数据对于建立全面的安全性档案至关重要。
{"title":"Hepatic Safety of Febuxostat and Allopurinol for Gout Patients: A Systematic Review of Randomized Controlled Trial.","authors":"Christiyanti Dewi,&nbsp;Falerina Puspita,&nbsp;Irma Melyani Puspitasari,&nbsp;Neily Zakiyah","doi":"10.2147/TCRM.S424598","DOIUrl":"https://doi.org/10.2147/TCRM.S424598","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to systematically review the hepatic safety of febuxostat and allopurinol in adult gout patients.</p><p><strong>Methods: </strong>We searched for information using the following databases: PubMed, Cochrane Library, and Scopus. The inclusion criteria were to review all randomized controlled trials (RCT) that compared allopurinol and febuxostat for adult gout patients that had an assessment of liver function outcomes. Non-English studies on case reports, case series, reviews, and abstracts only were excluded. We extracted information from the studies to answer the research question, ie, study design, publication year, population, sample size, patient characterization, duration, Jadad score, and liver function outcomes.</p><p><strong>Results: </strong>We screened 512 publications from the databases and identified 11 studies that met the inclusion criteria. Ten out of 11 included studies were double-blind RCTs. In the majority of the included studies, no statistically significant differences were observed in terms of hepatic safety data between febuxostat and allopurinol. However, in studies where allopurinol titration was used, it posed a challenge to maintain blinding. Notably, consistent adverse events related to liver function findings were observed across all reviewed RCTs. These abnormal liver function test results sometimes led to study withdrawal based on the investigators' assessment. Nevertheless, the investigators classified most liver function test elevations as mild to moderate in severity.</p><p><strong>Conclusion: </strong>Our analysis concluded that adult gout patients enrolled in the included RCTs exhibited similar hepatic safety profiles for both febuxostat and allopurinol treatment. Liver function abnormalities were identified in all RCTs included in this systematic review. Consequently, it is important for the product labeling information of both allopurinol and febuxostat to present and describe the current safety data to guide healthcare practitioners when prescribing these medications to patients. Pharmacovigilance and post-marketing pharmacoepidemiology data are essential in establishing the comprehensive safety profile.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ef/10/tcrm-19-731.PMC10516211.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41144253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fixation by Autogenous Cortical Plate Technique on Sites of Subtrochanteric Shortening Osteotomy Contributes to Early Bone Union in Total Hip Arthroplasty for Crowe Type IV Developmental Dysplasia of the Hip. 自体皮质钢板技术在粗隆下缩短截骨部位固定有助于Crowe IV型发育不良髋关节全髋关节置换术中早期骨愈合。
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-11-29 eCollection Date: 2022-01-01 DOI: 10.2147/TCRM.S381885
Yubo Liu, Shuai Zhang, Chao Li, Mingyang Ma, Minzhi Yang, Renwen Guo, Xiangpeng Kong, Wei Chai

Aim: Subtrochanteric shortening osteotomy (SSO) is often applied during total hip arthroplasty (THA) in high hip dislocations. The aim of the present paper was to evaluate the results of fixation by autogenous cortical plate technique on sites of SSO in THA for patients with Crowe type IV developmental dysplasia of the hip (DDH).

Methods: We conducted a historical prospective cohort study and reviewed 67 patients (82 THAs) with SSO performed between March 2016 and May 2020. Thirty-nine patients (48 hips) obtained stability by intramedullary pressure provided by the S-ROM modular prostheses and with or without prophylactic binding by stainless-steel wire after osteotomy and before stem implantation (group A). Twenty-eight patients (34 hips) were fixed with autogenous cortical plate technique and stainless-steel wire or cables (group B). Time of operations, complications, radiographic results and clinical scores were compared.

Results: One intraoperative fracture and a dislocation occurred, while component loosening, ectopic ossification and osteolysis were not observed. Group B had a higher union rate at the 4th month than group A (P = 0.015) while there were no significant differences of union rates at the 8th (P = 0.811) and the 12th month (P = 0.722) and of the average healing time (P = 0.181). No significant differences were found in hip function scores (HHS and WOMAC Osteoarthritis Index) between two groups.

Conclusion: Fixation with autogenous cortical plate from the cylinder of femoral bone contributes to early bone union of osteotomy ends in Crowe type IV DDH patients compared to those who do not apply the technique. Besides of application of autogenous cortical strut grafts, relevant measures are as well recommended to prevent nonunion after SSO.

目的:股骨粗隆下短截骨术(SSO)常用于高位髋关节脱位的全髋关节置换术(THA)。本研究的目的是评价自体皮质钢板技术在Crowe IV型发育不良髋关节(DDH)患者髋关节内单点韧带移位部位的固定效果。方法:我们进行了一项历史前瞻性队列研究,回顾了2016年3月至2020年5月期间接受SSO治疗的67例患者(82例tha)。39例(48髋)患者在截骨后和骨柄植入前通过S-ROM模数假体提供的髓内压力和有或没有预防性不锈钢丝捆绑获得稳定(A组)。28例(34髋)患者采用自体皮质钢板技术和不锈钢丝或电缆固定(B组)。比较手术时间、并发症、影像学结果和临床评分。结果:术中发生骨折1例,脱位1例,未见构件松动、异位骨化、骨溶解。B组4月愈合率高于a组(P = 0.015), 8月愈合率(P = 0.811)、12月愈合率(P = 0.722)及平均愈合时间(P = 0.181)差异无统计学意义。两组患者髋关节功能评分(HHS和WOMAC骨关节炎指数)无显著差异。结论:与未应用该技术的Crowe IV型DDH患者相比,股骨圆筒自体皮质钢板固定有助于截骨端早期骨愈合。除了应用自体皮质支架移植外,还建议采取相应措施预防单趾骨不连。
{"title":"Fixation by Autogenous Cortical Plate Technique on Sites of Subtrochanteric Shortening Osteotomy Contributes to Early Bone Union in Total Hip Arthroplasty for Crowe Type IV Developmental Dysplasia of the Hip.","authors":"Yubo Liu,&nbsp;Shuai Zhang,&nbsp;Chao Li,&nbsp;Mingyang Ma,&nbsp;Minzhi Yang,&nbsp;Renwen Guo,&nbsp;Xiangpeng Kong,&nbsp;Wei Chai","doi":"10.2147/TCRM.S381885","DOIUrl":"https://doi.org/10.2147/TCRM.S381885","url":null,"abstract":"<p><strong>Aim: </strong>Subtrochanteric shortening osteotomy (SSO) is often applied during total hip arthroplasty (THA) in high hip dislocations. The aim of the present paper was to evaluate the results of fixation by autogenous cortical plate technique on sites of SSO in THA for patients with Crowe type IV developmental dysplasia of the hip (DDH).</p><p><strong>Methods: </strong>We conducted a historical prospective cohort study and reviewed 67 patients (82 THAs) with SSO performed between March 2016 and May 2020. Thirty-nine patients (48 hips) obtained stability by intramedullary pressure provided by the S-ROM modular prostheses and with or without prophylactic binding by stainless-steel wire after osteotomy and before stem implantation (group A). Twenty-eight patients (34 hips) were fixed with autogenous cortical plate technique and stainless-steel wire or cables (group B). Time of operations, complications, radiographic results and clinical scores were compared.</p><p><strong>Results: </strong>One intraoperative fracture and a dislocation occurred, while component loosening, ectopic ossification and osteolysis were not observed. Group B had a higher union rate at the 4th month than group A (P = 0.015) while there were no significant differences of union rates at the 8th (P = 0.811) and the 12th month (P = 0.722) and of the average healing time (P = 0.181). No significant differences were found in hip function scores (HHS and WOMAC Osteoarthritis Index) between two groups.</p><p><strong>Conclusion: </strong>Fixation with autogenous cortical plate from the cylinder of femoral bone contributes to early bone union of osteotomy ends in Crowe type IV DDH patients compared to those who do not apply the technique. Besides of application of autogenous cortical strut grafts, relevant measures are as well recommended to prevent nonunion after SSO.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/45/44/tcrm-18-1059.PMC9719285.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35210820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hard-Candy Consumption Does Not Have an Effect on Volume and pH of Gastric Content in Patients Undergoing Elective Gastrointestinal Endoscopic Procedures: A Randomized Controlled Trial. 食用硬糖不会影响接受胃肠道内窥镜手术的患者胃内容物的体积和 pH 值:随机对照试验
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-11-28 eCollection Date: 2022-01-01 DOI: 10.2147/TCRM.S377421
Pawit Somnuke, Nuanprae Kitisin, Phornprasurt Chumklud, Pishsinee Kunavuttitagool, Penpuk Deepinta, Araya Wadrod, Warayu Prachayakul, Somchai Amornyotin, Nattaya Raykateeraroj

Purpose: This study aimed to determine the effect of hard candies on gastric content volume and pH in patients undergoing elective esophagogastroduodenoscopy and colonoscopy. Additionally, the study evaluated the difficulty of the procedure, complications, and satisfaction levels of the endoscopist and patient.

Patients and methods: A randomized controlled study equally recruited 108 outpatients to candy and control groups. The patients in the candy group could consume sugar-free candies within 2 hours before anesthesia, while the controls remained fasted. The endoscopic procedure began under topical pharyngeal anesthesia and intravenous sedation. A blinded endoscopist suctioned the gastric volume through an endoscope. A blinded anesthesia provider tested the gastric pH with a pH meter. The primary outcome variables were gastric volume and pH. The secondary outcome variables were complications, the difficulty of the procedure, and endoscopist and patient satisfaction.

Results: The characteristics of both patient groups were comparable. The mean gastric volume of the candy group (0.43 [0.27-0.67] mL/kg) was not significantly different from that of the control group (0.32 [0.19-0.55] mL/kg). The gastric pH of both groups was similar: 1.40 (1.10-1.70) for the candy group and 1.40 (1.20-1.90) for the control group. The procedure-difficulty score of the candy group was higher than that of the control group. The satisfaction scores rated by the endoscopist and the patients in both groups were comparable. In addition, most endoscopists and patients in the candy and control groups reported being "very satisfied". No complications were observed in either group.

Conclusion: Hard candies did not affect gastric volume or pH. Elective gastrointestinal endoscopic procedures in adult patients who preoperatively consume candies could proceed to prevent delays and disruption of workflows.

目的:本研究旨在确定硬糖对择期接受食管胃十二指肠镜检查和结肠镜检查的患者胃内容量和 pH 值的影响。此外,该研究还评估了手术的难度、并发症以及内镜医师和患者的满意度:随机对照研究将 108 名门诊患者平均分为糖果组和对照组。糖果组患者可在麻醉前 2 小时内食用无糖糖果,而对照组则保持空腹。内窥镜手术在局部咽部麻醉和静脉镇静的情况下开始。盲人内镜医师通过内镜抽吸胃液。盲人麻醉师用pH计测试胃的pH值。主要结果变量是胃容量和 pH 值。次要结果变量为并发症、手术难度以及内镜医师和患者的满意度:结果:两组患者的特征相当。糖果组的平均胃容量(0.43 [0.27-0.67] mL/kg)与对照组(0.32 [0.19-0.55] mL/kg)相比无显著差异。两组的胃 pH 值相似:糖果组为 1.40(1.10-1.70),对照组为 1.40(1.20-1.90)。糖果组的手术难度评分高于对照组。两组内镜医师和患者的满意度评分相当。此外,糖果组和对照组的大多数内镜医师和患者都表示 "非常满意"。两组均未发现并发症:结论:硬糖不会影响胃容量或胃酸pH值。对于术前食用糖果的成年患者,可继续进行选择性胃肠道内窥镜手术,以避免延误和中断工作流程。
{"title":"Hard-Candy Consumption Does Not Have an Effect on Volume and pH of Gastric Content in Patients Undergoing Elective Gastrointestinal Endoscopic Procedures: A Randomized Controlled Trial.","authors":"Pawit Somnuke, Nuanprae Kitisin, Phornprasurt Chumklud, Pishsinee Kunavuttitagool, Penpuk Deepinta, Araya Wadrod, Warayu Prachayakul, Somchai Amornyotin, Nattaya Raykateeraroj","doi":"10.2147/TCRM.S377421","DOIUrl":"10.2147/TCRM.S377421","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to determine the effect of hard candies on gastric content volume and pH in patients undergoing elective esophagogastroduodenoscopy and colonoscopy. Additionally, the study evaluated the difficulty of the procedure, complications, and satisfaction levels of the endoscopist and patient.</p><p><strong>Patients and methods: </strong>A randomized controlled study equally recruited 108 outpatients to candy and control groups. The patients in the candy group could consume sugar-free candies within 2 hours before anesthesia, while the controls remained fasted. The endoscopic procedure began under topical pharyngeal anesthesia and intravenous sedation. A blinded endoscopist suctioned the gastric volume through an endoscope. A blinded anesthesia provider tested the gastric pH with a pH meter. The primary outcome variables were gastric volume and pH. The secondary outcome variables were complications, the difficulty of the procedure, and endoscopist and patient satisfaction.</p><p><strong>Results: </strong>The characteristics of both patient groups were comparable. The mean gastric volume of the candy group (0.43 [0.27-0.67] mL/kg) was not significantly different from that of the control group (0.32 [0.19-0.55] mL/kg). The gastric pH of both groups was similar: 1.40 (1.10-1.70) for the candy group and 1.40 (1.20-1.90) for the control group. The procedure-difficulty score of the candy group was higher than that of the control group. The satisfaction scores rated by the endoscopist and the patients in both groups were comparable. In addition, most endoscopists and patients in the candy and control groups reported being \"very satisfied\". No complications were observed in either group.</p><p><strong>Conclusion: </strong>Hard candies did not affect gastric volume or pH. Elective gastrointestinal endoscopic procedures in adult patients who preoperatively consume candies could proceed to prevent delays and disruption of workflows.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ee/d7/tcrm-18-1049.PMC9716931.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35254377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quality and Characteristics of 4241 Case Reports of Lactic Acidosis in Metformin Users Reported to a Large Pharmacovigilance Database. 大型药物警戒数据库4241例二甲双胍使用者乳酸性酸中毒报告的质量和特点
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-11-04 eCollection Date: 2022-01-01 DOI: 10.2147/TCRM.S372430
Kerstin M G Brand, Judith Schlachter, Caroline Foch, Emmanuelle Boutmy

Objective: Metformin-associated lactic acidosis (MaLA) occurs rarely and is thus difficult to study. We analysed 4241 individual case safety reports of lactic acidosis (LA) that implicated metformin as a suspected drug reported to the pharmacovigilance database of Merck KGaA, Darmstadt, Germany. The primary objective was to review reports for quality and completeness of data to support diagnoses of MaLA. We also explored the correlations between reported biomarkers, and associations between biomarkers and outcomes.

Research design and methods: Records were analysed for completeness in supporting diagnoses of LA or metformin-associated LA (MaLA), against commonly used diagnostic criteria. Correlations between indices of exposure to metformin and biomarkers of LA and mortality were investigated.

Results: Missing data was common, especially for plasma metformin. Clinical/biomarker evidence supported a diagnosis of LA in only 33% of cases (LA subpopulation) and of MaLA in only 9% (MaLA subpopulation). The metformin plasma level correlated weakly with plasma lactate (positive) and pH (negative). About one-fifth (21.9%) of cases reported a fatal outcome. Metformin exposure (plasma level or dose) was not associated with increased mortality risk (there was a suggestion of decreased risk at higher levels of exposure to metformin). Plasma lactate was the only variable associated with increased risk of mortality. Examination of concomitant risk factors for MaLA identified renal dysfunction (including of iatrogenic origin) as a potential driver of mortality in this population.

Conclusion: Despite the high frequency of missing data, this is the largest analysis of cases of MaLA supported by measurements of circulating metformin, and lactate, and pH, to date. Plasma lactate, and not metformin dose or plasma level, appeared to be the main driver of mortality in the setting of LA or MaLA. Further research with more complete case reports is required.

目的:二甲双胍相关性乳酸酸中毒(MaLA)发病率低,研究难度大。我们分析了4241例乳酸性酸中毒(LA)的安全报告,这些报告涉及二甲双胍作为可疑药物,报告到德国达姆施塔特Merck KGaA的药物警戒数据库。主要目的是回顾报告的质量和数据的完整性,以支持MaLA的诊断。我们还探讨了已报道的生物标志物之间的相关性,以及生物标志物与预后之间的关联。研究设计和方法:对照常用的诊断标准,对支持LA或二甲双胍相关性LA (MaLA)诊断的记录进行完整性分析。研究了二甲双胍暴露指数与LA和死亡率生物标志物之间的相关性。结果:数据缺失很常见,尤其是血浆二甲双胍。临床/生物标志物证据仅支持33%的LA (LA亚群)和9%的MaLA (MaLA亚群)诊断为LA。血浆二甲双胍水平与血浆乳酸(阳性)和pH(阴性)呈弱相关。约五分之一(21.9%)的病例报告了死亡结果。二甲双胍暴露(血浆水平或剂量)与死亡风险增加无关(有迹象表明,二甲双胍暴露水平越高,死亡风险降低)。血浆乳酸是唯一与死亡风险增加相关的变量。对MaLA的伴随危险因素的检查发现,肾功能障碍(包括医源性)是该人群死亡的潜在驱动因素。结论:尽管数据丢失的频率很高,但这是迄今为止由循环二甲双胍、乳酸和pH测量支持的最大规模的MaLA病例分析。血浆乳酸,而不是二甲双胍剂量或血浆水平,似乎是LA或MaLA患者死亡率的主要驱动因素。需要进一步的研究和更完整的病例报告。
{"title":"Quality and Characteristics of 4241 Case Reports of Lactic Acidosis in Metformin Users Reported to a Large Pharmacovigilance Database.","authors":"Kerstin M G Brand,&nbsp;Judith Schlachter,&nbsp;Caroline Foch,&nbsp;Emmanuelle Boutmy","doi":"10.2147/TCRM.S372430","DOIUrl":"https://doi.org/10.2147/TCRM.S372430","url":null,"abstract":"<p><strong>Objective: </strong>Metformin-associated lactic acidosis (MaLA) occurs rarely and is thus difficult to study. We analysed 4241 individual case safety reports of lactic acidosis (LA) that implicated metformin as a suspected drug reported to the pharmacovigilance database of Merck KGaA, Darmstadt, Germany. The primary objective was to review reports for quality and completeness of data to support diagnoses of MaLA. We also explored the correlations between reported biomarkers, and associations between biomarkers and outcomes.</p><p><strong>Research design and methods: </strong>Records were analysed for completeness in supporting diagnoses of LA or metformin-associated LA (MaLA), against commonly used diagnostic criteria. Correlations between indices of exposure to metformin and biomarkers of LA and mortality were investigated.</p><p><strong>Results: </strong>Missing data was common, especially for plasma metformin. Clinical/biomarker evidence supported a diagnosis of LA in only 33% of cases (LA subpopulation) and of MaLA in only 9% (MaLA subpopulation). The metformin plasma level correlated weakly with plasma lactate (positive) and pH (negative). About one-fifth (21.9%) of cases reported a fatal outcome. Metformin exposure (plasma level or dose) was not associated with increased mortality risk (there was a suggestion of decreased risk at higher levels of exposure to metformin). Plasma lactate was the only variable associated with increased risk of mortality. Examination of concomitant risk factors for MaLA identified renal dysfunction (including of iatrogenic origin) as a potential driver of mortality in this population.</p><p><strong>Conclusion: </strong>Despite the high frequency of missing data, this is the largest analysis of cases of MaLA supported by measurements of circulating metformin, and lactate, and pH, to date. Plasma lactate, and not metformin dose or plasma level, appeared to be the main driver of mortality in the setting of LA or MaLA. Further research with more complete case reports is required.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2022-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ae/13/tcrm-18-1037.PMC9642855.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40709321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Therapeutics and Clinical Risk Management
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1